相似文献
1
Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer.PPARγ配体的抗癌作用：人类肺癌的现状与未来展望
World J Biol Chem. 2010 Mar 26;1(3):31-40. doi: 10.4331/wjbc.v1.i3.31.
2
Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy.过氧化物酶体增殖物激活受体γ与肺癌生物学：对治疗的启示
J Investig Med. 2008 Feb;56(2):528-33. doi: 10.2310/JIM.0b013e3181659932.
3
Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.过氧化物酶体增殖物激活受体γ在膀胱癌中的作用：一个有前景的治疗靶点。
Cancer Biol Ther. 2009 Apr;8(7):6-15. doi: 10.4161/cbt.8.7.7853.
4
The Role of PPARs in Disease.过氧化物酶体增殖物激活受体（PPARs）在疾病中的作用。
Cells. 2020 Oct 28;9(11):2367. doi: 10.3390/cells9112367.
5
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.过氧化物酶体增殖物激活受体与动脉粥样硬化形成：血管细胞中基因表达的调节因子
Circ Res. 2004 May 14;94(9):1168-78. doi: 10.1161/01.RES.0000127122.22685.0A.
6
The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity.过氧化物酶体增殖物激活受体γ（PPARγ）配体对癌细胞致瘤性的影响。
Gene. 2018 Apr 5;649:14-22. doi: 10.1016/j.gene.2018.01.018. Epub 2018 Jan 31.
7
Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.编辑精选：PPARβ/δ 和 PPARγ 通过调节炎症和细胞凋亡抑制黑色素瘤的肿瘤发生。
Toxicol Sci. 2017 Oct 1;159(2):436-448. doi: 10.1093/toxsci/kfx147.
8
PPAR ligands: are they potential agents for cardiovascular disorders?过氧化物酶体增殖物激活受体配体：它们是心血管疾病的潜在治疗药物吗？
Pharmacology. 2007;80(1):1-10. doi: 10.1159/000102594. Epub 2007 May 10.
9
Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.过氧化物酶体增殖物激活受体（PPAR）α和PPARβ/δ而非PPARγ，调节参与心脏脂质代谢的基因的表达。
Circ Res. 2003 Mar 21;92(5):518-24. doi: 10.1161/01.RES.0000060700.55247.7C. Epub 2003 Feb 6.
10
Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.过氧化物酶体增殖物激活受体（PPARs）与人体皮肤：PPARs在皮肤生理学和皮肤病中的重要性
Am J Clin Dermatol. 2008;9(1):15-31. doi: 10.2165/00128071-200809010-00002.
引用本文的文献
1
Bezafibrate-driven mitochondrial targeting enhances antitumor immunity and prevents lung cancer via CD8+ T cell infiltration and MDSC reduction.苯扎贝特驱动的线粒体靶向通过CD8 + T细胞浸润和髓系来源抑制细胞减少增强抗肿瘤免疫力并预防肺癌。
Front Immunol. 2025 Apr 15;16:1539808. doi: 10.3389/fimmu.2025.1539808. eCollection 2025.
2
The Potential Role of PPARs in the Fetal Origins of Adult Disease.过氧化物酶体增殖物激活受体（PPARs）在成年疾病胎儿起源中的潜在作用。
Cells. 2022 Nov 2;11(21):3474. doi: 10.3390/cells11213474.
3
Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists.含磺酰基硫脲基团的噻唑烷-2,4-二酮类化合物作为有效的血管内皮生长因子受体-2（VEGFR-2）抑制剂和过氧化物酶体增殖物激活受体γ（PPARγ）激动剂的设计、分子对接、合成、抗癌及抗高血糖活性评估
Pharmaceuticals (Basel). 2022 Feb 14;15(2):226. doi: 10.3390/ph15020226.
4
A novel PPARɣ ligand, PPZ023, overcomes radioresistance via ER stress and cell death in human non-small-cell lung cancer cells.新型过氧化物酶体增殖物激活受体γ配体 PPZ023 通过内质网应激和细胞死亡克服人非小细胞肺癌细胞的放射抵抗性。
Exp Mol Med. 2020 Oct;52(10):1730-1743. doi: 10.1038/s12276-020-00511-9. Epub 2020 Oct 12.
5
Critical role of PPARγ in myeloid-derived suppressor cell-stimulated cancer cell proliferation and metastasis.过氧化物酶体增殖物激活受体γ在髓源性抑制细胞刺激的癌细胞增殖和转移中的关键作用。
Oncotarget. 2016 Jan 12;7(2):1529-43. doi: 10.18632/oncotarget.6414.
本文引用的文献
1
Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer.过氧化物酶体增殖物激活受体-α和-γ在非小细胞肺癌发展中的作用。
Am J Respir Cell Mol Biol. 2010 Dec;43(6):674-83. doi: 10.1165/rcmb.2009-0349OC. Epub 2010 Jan 15.
2
alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer.α5β1 整合素表达对于实验性肺癌肿瘤进展是必需的。
Am J Respir Cell Mol Biol. 2010 Dec;43(6):684-91. doi: 10.1165/rcmb.2009-0375OC. Epub 2010 Jan 15.
3
Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.激活过氧化物酶体增殖物激活受体γ突变体通过增强血管生成促进体内肿瘤生长。
Cancer Res. 2009 Dec 15;69(24):9236-44. doi: 10.1158/0008-5472.CAN-09-2067.
4
The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.曲格列酮联合阿司匹林的协同抗癌作用导致人肺癌细胞周期停滞和凋亡。
Mol Carcinog. 2010 Mar;49(3):235-46. doi: 10.1002/mc.20593.
5
Tobacco control in the United States--recent progress and opportunities.美国的烟草控制——近期进展与机遇
CA Cancer J Clin. 2009 Nov-Dec;59(6):352-65. doi: 10.3322/caac.20037.
6
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.罗格列酮可预防小鼠模型中肺癌前病变的进展。
Carcinogenesis. 2009 Dec;30(12):2095-9. doi: 10.1093/carcin/bgp260.
7
Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.新型 α-杂芳基-苯基丙酸衍生物的合成与评价及其作为过氧化物酶体增殖物激活受体 α/γ 双重激动剂的活性。
Bioorg Med Chem. 2009 Oct 15;17(20):7113-25. doi: 10.1016/j.bmc.2009.09.001. Epub 2009 Sep 6.
8
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.新型2-芳氧基-3-苯基丙酸作为过氧化物酶体增殖物激活受体α/γ双重激动剂，具有更高的效力和对骨骼肌功能更低的不良反应。
J Med Chem. 2009 Oct 22;52(20):6382-93. doi: 10.1021/jm900941b.
9
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.DH9，一种新型的过氧化物酶体增殖物激活受体γ激动剂，可抑制 ADPKD 上皮细胞的增殖：与抑制β-连环蛋白信号有关。
Invest New Drugs. 2010 Dec;28(6):783-90. doi: 10.1007/s10637-009-9313-x. Epub 2009 Sep 16.
10
Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.晚期非小细胞肺癌治疗中的靶向治疗：最新进展
Klin Onkol. 2009;22(4):131-8.
Zotero 插件